About InVivoSIM anti-human VEGF (Bevacizumab Biosimilar) This non-therapeutic biosimilar antibody uses the same variable regions from the therapeutic antibody Bevacizumab making it ideal for research use. This Bevacizumab biosimilar reacts with human VEGF (vascular endothelial growth factor). VEGF is a 45 kDa homodimeric, disulfide-linked glycoprotein that plays key roles in angiogenesis, vasculogenesis, and endothelial cell growth. It promotes mitogenesis, chemotaxis, and vascular permeability. Most tumors have a requirement for angiogenesis, and inhibition of VEGF biding to VEGF receptors has been the focus of several tumor therapeutic strategies. Bevacizumab neutralizes the biological activity of VEGF by preventing the interaction of VEGF with its receptors on the surface of endothelial cells, resulting in the inhibition of tumor growth. InVivoSIM anti-human VEGF (Bevacizumab Biosimilar) Specifications IsotypeHuman IgG1 Recommended Isotype Control(s)RecombiMAb human IgG1 isotype control, anti-hen egg lysozyme Recommended Dilution BufferInVivoPure pH 7.0 Dilution Buffer ImmunogenHuman VEGF Reported ApplicationsVEGF neutralizationFlow CytometryELISAImmunoprecipitationWestern Block FormulationPBS, pH 7.0 Contains no stabilizers or preservatives Endotoxin<1EU/mg (<0.001EU/μg) Determined by LAL gel clotting assay Aggregation<5% Determined by SEC Purity>95% Determined by SDS-PAGE Sterility0.2 μm filtration ProductionPurified from cell culture supernatant in an animal-free facility PurificationProtein A RRIDAB_2894728 Molecular Weight150 kDa StorageThe antibody solution should be stored at the stock concentration at 4°C. Do not freeze.
